Dosage regimes for the administration of an anti-CD19 ADC
US11318211B2 · kind B2 · utility
1Cited by
96References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 14, 2018 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | Jun 14, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.